Navigation Links
Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
Date:8/23/2013

Jacksonville, FL and Savannah, GA (PRWEB) August 23, 2013

Morphogenesis Inc., a biotechnology firm that has developed a specialized process that educates the immune system to fight cancer in dogs, cats and horses, announces the start of a field study for its personalized cancer treatment for dogs in partnership with SEVO-Med (Southeastern Veterinary Oncology and Medicine).

Tampa-based Morphogenesis and SEVO-Med, a major southeastern veterinary oncology practice which has clinics in Jacksonville and Savannah, are providing the opportunity to pet owners and veterinarians to enroll dogs with High Grade B Cell Lymphoma who might benefit from this personalized treatment.

The first 20 dogs who qualify for the study will be selected. Veterinarians and dog owners who believe their patient/pet could qualify to participate in the study should immediately contact SEVO-Med at 904-278-3870 or 912-355-5791. Once a dog is accepted into the study, treatments and study tests are provided at no cost to the owner.

The vaccine-based cancer treatments developed by Morphogenesis have been shown to manage 17 types of cancer without any side effects in canine, feline and equine patients.

In the treatment developed by Morphogenesis, the dog’s own lymphoma cells undergo a marking process that helps the animal’s immune system recognize the cells as foreign and kill them.

“We educate the body’s immune system to fight its own tumor cells,” said Pat Lawman, Ph.D., CEO of Morphogenesis. “Our process helps keep the cancer in check so that it doesn't progress, and we all think that’s a win.”

“More and more, you are seeing companion animals present with all types of cancers,” Tracy LaDue, DVM, founder of SEVO-Med, wrote in letters to veterinarians informing them of this treatment option for qualifying dogs. “The study being conducted by Morphogenesis and SEVO-Med will further demonstrate the safety and effectiveness of this cutting edge new technology in the fight against lymphoma.”    

About SEVO-Med

Southeast Veterinary Oncology (SEVO) was founded in the Jacksonville suburb of Orange Park, FL, in October, 2004 by double-board certified veterinary oncologist, Tracy LaDue, DVM. At that time, SEVO was one of the first oncology-specific veterinary specialty practices in the U.S. The practice opened its Savannah, GA, clinic in September of 2011. Today, the practices are led by Dr. LaDue and Jennifer Locke, DVM in Florida, and Andrew Daters, DVM, in Georgia. SEVO-Med’s mission is to understand the unique and special bond shared between you and your pet, to offer compassionate guidance, to deliver excellent state of the art medical care, to provide the utmost in client communication and to collaborate with referring veterinarians to develop the best therapy for your pet. For more information, please visit http://www.petcancercare.com or call 904-278-3870 or 912-355-5791.

About Morphogenesis

Morphogenesis is a privately-held biotechnology company structured to serve the rapidly growing cell therapy, biologics and tissue engineering markets. Morphogenesis has developed a multi-indication cancer therapy which educates the immune system to attack tumor cells throughout the body without damaging other cells or systems. Its subsidiary, Veterinary Oncology Services, Inc., assists veterinary physicians in providing this non-toxic, personalized treatment for many types of cancers in cats, dogs and horses. For more information, please visit http://www.veterinaryoncologyservices.com or 813-877-7896 http://www.morphogenesis-inc.com or call 813-875-6600.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11054809.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
2. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
3. NYSCF scientists create personalized bone substitutes from skin cells
4. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
5. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
6. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
7. Transplanted brain cells in monkeys light up personalized therapy
8. Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - 2013 Report
9. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... conditions have influenced the most recent performances of select ... (NASDAQ: RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... by Grand View Research, global Biotech market size is expected to ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
Breaking Biology Technology:
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):